vs
碧迪（BDX）与Builders FirstSource（BLDR）财务数据对比。点击上方公司名可切换其他公司
碧迪的季度营收约是Builders FirstSource的1.6倍（$5.3B vs $3.4B），碧迪净利率更高（7.3% vs 0.9%，领先6.3%），碧迪同比增速更快（-0.4% vs -12.1%），碧迪自由现金流更多（$549.0M vs $106.7M），过去两年碧迪的营收复合增速更高（2.0% vs -7.1%）
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
Builders FirstSource是财富500强企业，成立于1998年3月，总部位于美国得克萨斯州欧文，是美国规模最大的建筑产品、预制构件及增值服务供应商，同时生产制造建筑材料。公司在全美拥有超1.5万名员工，服务于新建住宅施工、维修及翻新领域的专业客户。
BDX vs BLDR — 直观对比
营收规模更大
BDX
是对方的1.6倍
$3.4B
营收增速更快
BDX
高出11.7%
-12.1%
净利率更高
BDX
高出6.3%
0.9%
自由现金流更多
BDX
多$442.3M
$106.7M
两年增速更快
BDX
近两年复合增速
-7.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.3B | $3.4B |
| 净利润 | $382.0M | $31.5M |
| 毛利率 | 45.9% | 29.8% |
| 营业利润率 | 10.5% | 1.8% |
| 净利率 | 7.3% | 0.9% |
| 营收同比 | -0.4% | -12.1% |
| 净利润同比 | 24.0% | -83.5% |
| 每股收益（稀释后） | $1.34 | $0.29 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDXBLDR
| Q4 25 | $5.3B | $3.4B | ||
| Q3 25 | $5.9B | $3.9B | ||
| Q2 25 | $5.5B | $4.2B | ||
| Q1 25 | $5.3B | $3.7B | ||
| Q4 24 | $5.2B | $3.8B | ||
| Q3 24 | $5.4B | $4.2B | ||
| Q2 24 | $5.0B | $4.5B | ||
| Q1 24 | $5.0B | $3.9B |
净利润BDXBLDR
| Q4 25 | $382.0M | $31.5M | ||
| Q3 25 | $493.0M | $122.4M | ||
| Q2 25 | $574.0M | $185.0M | ||
| Q1 25 | $308.0M | $96.3M | ||
| Q4 24 | $303.0M | $190.2M | ||
| Q3 24 | $400.0M | $284.8M | ||
| Q2 24 | $487.0M | $344.1M | ||
| Q1 24 | $537.0M | $258.8M |
毛利率BDXBLDR
| Q4 25 | 45.9% | 29.8% | ||
| Q3 25 | 47.5% | 30.4% | ||
| Q2 25 | 47.8% | 30.7% | ||
| Q1 25 | 42.8% | 30.5% | ||
| Q4 24 | 43.2% | 32.3% | ||
| Q3 24 | 45.7% | 32.8% | ||
| Q2 24 | 46.2% | 32.8% | ||
| Q1 24 | 45.7% | 33.4% |
营业利润率BDXBLDR
| Q4 25 | 10.5% | 1.8% | ||
| Q3 25 | 11.8% | 5.8% | ||
| Q2 25 | 16.0% | 7.4% | ||
| Q1 25 | 10.4% | 5.0% | ||
| Q4 24 | 8.8% | 8.0% | ||
| Q3 24 | 11.4% | 10.1% | ||
| Q2 24 | 12.1% | 11.0% | ||
| Q1 24 | 14.5% | 9.6% |
净利率BDXBLDR
| Q4 25 | 7.3% | 0.9% | ||
| Q3 25 | 8.4% | 3.1% | ||
| Q2 25 | 10.4% | 4.4% | ||
| Q1 25 | 5.8% | 2.6% | ||
| Q4 24 | 5.9% | 5.0% | ||
| Q3 24 | 7.4% | 6.7% | ||
| Q2 24 | 9.8% | 7.7% | ||
| Q1 24 | 10.6% | 6.7% |
每股收益（稀释后）BDXBLDR
| Q4 25 | $1.34 | $0.29 | ||
| Q3 25 | $1.71 | $1.10 | ||
| Q2 25 | $2.00 | $1.66 | ||
| Q1 25 | $1.07 | $0.84 | ||
| Q4 24 | $1.04 | $1.65 | ||
| Q3 24 | $1.37 | $2.44 | ||
| Q2 24 | $1.68 | $2.87 | ||
| Q1 24 | $1.85 | $2.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $740.0M | $181.8M |
| 总债务越低越好 | — | $4.4B |
| 股东权益账面价值 | $25.3B | $4.4B |
| 总资产 | $54.8B | $11.2B |
| 负债/权益比越低杠杆越低 | — | 1.02× |
8季度趋势，按日历期对齐
现金及短期投资BDXBLDR
| Q4 25 | $740.0M | $181.8M | ||
| Q3 25 | $641.0M | $296.2M | ||
| Q2 25 | $735.0M | $87.0M | ||
| Q1 25 | $667.0M | $115.4M | ||
| Q4 24 | $711.0M | $153.6M | ||
| Q3 24 | $1.7B | $328.1M | ||
| Q2 24 | $4.5B | $75.6M | ||
| Q1 24 | $2.3B | $697.5M |
总债务BDXBLDR
| Q4 25 | — | $4.4B | ||
| Q3 25 | — | $4.4B | ||
| Q2 25 | — | $4.7B | ||
| Q1 25 | — | $4.5B | ||
| Q4 24 | — | $3.7B | ||
| Q3 24 | — | $3.7B | ||
| Q2 24 | — | $3.8B | ||
| Q1 24 | — | $3.7B |
股东权益BDXBLDR
| Q4 25 | $25.3B | $4.4B | ||
| Q3 25 | $25.4B | $4.3B | ||
| Q2 25 | $25.5B | $4.2B | ||
| Q1 25 | $25.2B | $4.4B | ||
| Q4 24 | $25.2B | $4.3B | ||
| Q3 24 | $25.9B | $4.4B | ||
| Q2 24 | $25.9B | $4.3B | ||
| Q1 24 | $25.6B | $5.0B |
总资产BDXBLDR
| Q4 25 | $54.8B | $11.2B | ||
| Q3 25 | $55.3B | $11.4B | ||
| Q2 25 | $54.9B | $11.5B | ||
| Q1 25 | $54.5B | $11.4B | ||
| Q4 24 | $54.7B | $10.6B | ||
| Q3 24 | $57.3B | $10.9B | ||
| Q2 24 | $55.6B | $10.7B | ||
| Q1 24 | $54.2B | $11.2B |
负债/权益比BDXBLDR
| Q4 25 | — | 1.02× | ||
| Q3 25 | — | 1.03× | ||
| Q2 25 | — | 1.12× | ||
| Q1 25 | — | 1.02× | ||
| Q4 24 | — | 0.86× | ||
| Q3 24 | — | 0.83× | ||
| Q2 24 | — | 0.88× | ||
| Q1 24 | — | 0.75× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $657.0M | $194.8M |
| 自由现金流经营现金流 - 资本支出 | $549.0M | $106.7M |
| 自由现金流率自由现金流/营收 | 10.5% | 3.2% |
| 资本支出强度资本支出/营收 | 2.1% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.72× | 6.19× |
| 过去12个月自由现金流最近4个季度 | $2.6B | $853.3M |
8季度趋势，按日历期对齐
经营现金流BDXBLDR
| Q4 25 | $657.0M | $194.8M | ||
| Q3 25 | $1.4B | $547.7M | ||
| Q2 25 | $1.2B | $341.0M | ||
| Q1 25 | $164.0M | $132.3M | ||
| Q4 24 | $693.0M | $373.5M | ||
| Q3 24 | $1.2B | $730.0M | ||
| Q2 24 | $1.3B | $452.1M | ||
| Q1 24 | $514.0M | $317.2M |
自由现金流BDXBLDR
| Q4 25 | $549.0M | $106.7M | ||
| Q3 25 | $1.0B | $461.9M | ||
| Q2 25 | $1.0B | $252.3M | ||
| Q1 25 | $35.0M | $32.4M | ||
| Q4 24 | $588.0M | $273.8M | ||
| Q3 24 | $882.0M | $630.4M | ||
| Q2 24 | $1.1B | $364.0M | ||
| Q1 24 | $380.0M | $224.0M |
自由现金流率BDXBLDR
| Q4 25 | 10.5% | 3.2% | ||
| Q3 25 | 17.0% | 11.7% | ||
| Q2 25 | 19.0% | 6.0% | ||
| Q1 25 | 0.7% | 0.9% | ||
| Q4 24 | 11.4% | 7.2% | ||
| Q3 24 | 16.2% | 14.9% | ||
| Q2 24 | 22.4% | 8.2% | ||
| Q1 24 | 7.5% | 5.8% |
资本支出强度BDXBLDR
| Q4 25 | 2.1% | 2.6% | ||
| Q3 25 | 6.0% | 2.2% | ||
| Q2 25 | 3.2% | 2.1% | ||
| Q1 25 | 2.4% | 2.7% | ||
| Q4 24 | 2.0% | 2.6% | ||
| Q3 24 | 5.4% | 2.4% | ||
| Q2 24 | 3.6% | 2.0% | ||
| Q1 24 | 2.7% | 2.4% |
现金转化率BDXBLDR
| Q4 25 | 1.72× | 6.19× | ||
| Q3 25 | 2.75× | 4.48× | ||
| Q2 25 | 2.12× | 1.84× | ||
| Q1 25 | 0.53× | 1.37× | ||
| Q4 24 | 2.29× | 1.96× | ||
| Q3 24 | 2.94× | 2.56× | ||
| Q2 24 | 2.66× | 1.31× | ||
| Q1 24 | 0.96× | 1.23× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
BLDR
| Specialty Building Products And Services | $949.0M | 28% |
| Windows Doors And Millwork | $893.5M | 27% |
| Lumber And Lumber Sheet Goods | $772.6M | 23% |
| Manufactured Products | $742.8M | 22% |
